SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : ADVR:THE NEW COMPANY...WITH A NEW LIFE...AND A NEW MISSION
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BARRY ALLEN who wrote (294)6/4/1998 9:54:00 AM
From: Bernie Bildman  Read Replies (1) of 4891
 
So far as I know, Rebetron has been _APPROVED_ by the FDA for the treatment of Hepatitis C. Reticulose, far as I can surmise, isn't slightly close to being approved for even _TESTING_ (by the US FDA) for any malady at this point in time.

I say this only to point out it doesn't do us much good to talk about all the "serious side effects" of other drugs.

At least other companies are moving along in the test and approval process, something which Reticulose doesn't seem to be doing.

If they are, we sure aren't being told about it.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News